Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 290 of 5804
-
New drug cocktail aims to boost immune attack on lung cancer
Disease control Not yet recruiting* In this study, we hypothesized that immune engagement by amivantamab will enhance antitumor efficacy by modulating the immune microenvironment in combination with lazertinib in patients with untreated EGFR-mutant NSCLC or with chemotherapy (carboplatin plus pemetrexed) after pr…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could immunotherapy spare throat cancer patients from losing their voice?
Disease control Recruiting nowThis trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
Phase: PHASE2 • Sponsor: Matthew Spector • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill aims to slow lung decline in scarring disease
Disease control Not yet recruitingThis study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for lung scarring: HSK44459 enters final trial phase
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New breast cancer trial aims to spare heart toxicity with smart drug strategy
Disease control Not yet recruitingIparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage bre…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Tiny particles packed with steroids could restore hearing
Disease control Recruiting nowPrimary Objective To compare the efficacy of a single course of IT Exo-Dex versus conventional IT dexamethasone and exosome vehicle alone, as measured by the mean change in pure-tone average (PTA; 0.5, 1, 2, 4 kHz) from baseline to the 4-week post-treatment endpoint. Secondary O…
Phase: NA • Sponsor: Kafrelsheikh University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for lung cancer: experimental drug RC148 takes on standard therapy
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Part…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for stroke prevention in heart patients who Can't use standard meds
Disease control Recruiting nowThis study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to stop prostate cancer spread in high-risk patients
Disease control Recruiting nowThe advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e.,…
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug aims to stop Alzheimer's before it starts in gene carriers
Prevention Not yet recruitingPrimary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau relate…
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC
-
Invisible hearing implant could change lives of those with severe hearing loss
Disease control Recruiting nowThis pivotal study examines the clinical efficacy and safety of an investigational totally implantable cochlear implant (TICI) system. The system includes a microphone placed under the skin to detect speech and sound from the environment, providing the option to hear without any …
Phase: NA • Sponsor: Cochlear • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New yearly shot could help SMA patients move better
Disease control Recruiting nowIn this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis study is a multicenter, randomized, two-cohort clinical trial to evaluate the efficacy and safety of SHR-1701 with or without apatinib in combined with chemotherapy of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New lupus drug candidate enters Mid-Stage testing
Disease control Recruiting nowThis study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment p…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New PTSD drug shows promise in Large-Scale trial
Symptom relief Recruiting nowThis study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, par…
Phase: PHASE3 • Sponsor: Transcend Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New RNA drug shows promise in preventing HAE attacks in ongoing study
Disease control Recruiting nowStudy ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New chemo cocktail aims to shrink pancreatic tumors
Disease control Recruiting nowThis is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Light-Activated gel could save diabetic feet from amputation
Disease control Recruiting nowProtocol No. CHLORIN E6-IIB/III-01/Protocol/1.1 Title:Single-Centre, open-labeled, randomized, Phase IIb and Phase III clinical studies to evaluate the safety, tolerability, and efficacy of Chlorin E6 (Gel Formation) as a photosensitizing agent for the management of Diabetic Foot…
Phase: PHASE3 • Sponsor: United Medical and Dental College • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control Not yet recruitingThis phase II trial tests how well giving Y-90 radioembolization, durvalumab, tremelimumab and zanzalintinib works for the treatment of hepatocellular carcinoma that cannot be removed by surgery (unresectable) and that has spread to nearby tissue or lymph nodes (locally advanced)…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail shows promise for rare sarcoma
Disease control Recruiting nowThis is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC